posted on 2017-11-29, 12:01authored byMatias C. Vieira, Lucilla Poston, Elaine Fyfe, Alexandra Gillett, Louise C. Kenny, Claire T. Roberts, Philip N. Baker, Jenny E. Myers, James J. Walker, Lesley M. McCowan, Robyn A. North, Dharmintra Pasupathy, SCOPE Consortium
OBJECTIVE: To compare early pregnancy clinical and biomarker risk factors for later development of preeclampsia between women with obesity (body mass index, BMI ≥30 kg/m(2) ) and those with a normal BMI (20-25 kg/m(2) ). METHODS: In 3,940 eligible nulliparous women from the Screening for Pregnancy Endpoints (SCOPE) study, a total of 53 biomarkers of glucose and lipid metabolism, placental function, and known markers of preeclampsia were measured at 14 to 16 weeks' gestation. Logistic regression was performed to identify clinical and biomarker risk factors for preeclampsia in women with and without obesity. RESULTS: Among 834 women with obesity and 3,106 with a normal BMI, 77 (9.2%) and 105 (3.4%) developed preeclampsia, respectively. In women with obesity, risk factors included a family history of thrombotic disease, low plasma placental growth factor, and higher uterine artery resistance index at 20 weeks. In women with a normal BMI, a family history of preeclampsia or gestational hypertension, mean arterial blood pressure, plasma endoglin and cystatin C, and uterine artery resistance index were associated with preeclampsia, while high fruit intake was protective. CONCLUSIONS: Women with obesity and a normal BMI have different early pregnancy clinical and biomarker risk factors for preeclampsia.
Funding
MCV is supported by a Science Without Borders Fellowship, Brazil (BEX: 9571/13-2). LCK is supported by a Science Foundation Ireland Program Grant for INFANT (12/RC/2272). CTR is supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship APP1020749. The SCOPE database is provided and maintained by MedSciNet AB (http://medscinet.com). SCOPE study funding: University of Auckland, the New Enterprise Research Fund, Foundation for Research Science and Technology, Health Research Council, Evelyn Bond Fund, Auckland District Health Board Charitable Trust. University of Adelaide, the Premier's Science and Research Fund, South Australian Government. University of Cork, Ireland, the Health Research Board of Ireland. University of Manchester, National Health Service NEAT Grant, Biotechnology and Biological Sciences Research Council, the University of Manchester Proof of Concept Funding. King's College London, Guy's and St. Thomas' Charity, Tommy's Charity. University of Leeds, Cerebra UK, NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. Biomarker analysis was funded by an unrestricted research grant from Alere Inc, San Diego, CA (www.alere.com), to the universities in the SCOPE Consortium.
The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.